SB431542-Loaded Liposomes Alleviate Liver Fibrosis by Suppressing TGF-β Signaling
Authors:
- 22 October 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 17 (11) , 4152-4162
Abstract
Liver fibrosis is a common outcome of most chronic liver diseases, but there is no clinically approved drug for its treatment. Previous studies have reported the potential of SB431542 as an inhibitor of TGF-β signaling in the treatment of liver fibrosis, but it shows poor water solubility and low bioavailability. Here, we improve these characteristics of SB431542 by loading it into liposomes (SB-Lips) with two FDA-approved excipients: soya phosphatidyl S100 and Solutol HS15. In vitro, SB-Lips had stronger inhibitory effects on the proliferation and activation of hepatic stellate cells LX-2 than free SB. After an intravenous injection in a CCl4-induced liver fibrosis mouse model, SB-Lips accumulated preferentially in the liver, its area under the concentration–time curve was significantly higher than that of free SB431542, and it alleviated hepatic fibrosis significantly more than free drug, which was associated with greater inhibition of TGF-β signaling. Furthermore, SB-Lips did not cause significant injury to other organs. These results suggest that our liposomal system is safe and effective for delivering SB431542 to fibrotic liver.Keywords
Funding Information
- National Natural Science Foundation of China (81870599, 81873662, 81930020)
- Sichuan Province (2020YFS0064)
- West China Hospital, Sichuan University (2018HXBH060)
This publication has 42 references indexed in Scilit:
- Molecular pathogenesis of hepatic fibrosis and current therapeutic approachesChemico-Biological Interactions, 2011
- Role of Smads in TGFβ signalingCell and tissue research, 2011
- Preparation and evaluation of novel mixed micelles as nanocarriers for intravenous delivery of propofolDiscover Nano, 2011
- The Effect of Novel Surfactants and Solutol® HS 15 on Paclitaxel Aqueous Solubility and Permeability Across a Caco-2 MonolayerJournal of Pharmaceutical Sciences, 2010
- Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the LiverPhysiological Reviews, 2008
- SB-431542, a Transforming Growth Factor β Inhibitor, ImpairsTrypanosoma cruziInfection in Cardiomyocytes and Parasite Cycle CompletionAntimicrobial Agents and Chemotherapy, 2007
- Targeted and regulable expression of transgenes in hepatic stellate cells and myofibroblasts in culture and in vivo using an adenoviral Cre/loxP system to antagonise hepatic fibrosisGut, 2006
- Inhibition of TGF‐β signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine‐induced liver fibrosisBritish Journal of Pharmacology, 2005
- Liver fibrosis – from bench to bedsideJournal of Hepatology, 2003
- SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7Molecular Pharmacology, 2002